Sacral neuromodulation versus personalized conservative treatment in patients with idiopathic slow-transit constipation: study protocol of the No.2-trial, a multicenter open-label randomized controlled trial and cost-effectiveness analysis.

Heemskerk, S C M; Rotteveel, A H; Benninga, M A; Baeten, C I M; Masclee, A A M; Melenhorst, J; van Kuijk, S M J; Dirksen, C D; Breukink, S O

Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item. When enough users have cast their vote on this item, the average rating will also be shown.

Star rating

Your vote was cast
Thank you for your feedback

Authors

Heemskerk, S C M
Rotteveel, A H
Benninga, M A
Baeten, C I M
Masclee, A A M
Melenhorst, J
van Kuijk, S M J
Dirksen, C D
Breukink, S O

Type

Article

Language

Metadata

Show full item record

Title

Sacral neuromodulation versus personalized conservative treatment in patients with idiopathic slow-transit constipation: study protocol of the No.2-trial, a multicenter open-label randomized controlled trial and cost-effectiveness analysis.

Published in

Int J Colorectal Dis 2018; 33(4):493-501

Publiekssamenvatting

The evidence regarding the (cost-)effectiveness of sacral neuromodulation (SNM) in patients with therapy-resistant idiopathic slow-transit constipation is of suboptimal quality. The Dutch Ministry of Health, Welfare and Sports has granted conditional reimbursement for SNM treatment. The objective is to assess the effectiveness, cost-effectiveness, and budget impact of SNM compared to personalized conservative treatment (PCT) in patients with idiopathic slow-transit constipation refractory to conservative treatment.